Evidence map›Paper›PMID 39253487›Full record

ArticlebioRxiv : the preprint server for biology2024

TUMOR-INFILTRATING NOCICEPTOR NEURONS PROMOTE IMMUNOSUPPRESSION.

Anthony C Restaino, Maryam Ahmadi, Amin Reza Nikpoor, Austin Walz, Mohammad Balood, Tuany Eichwald, Sebastien Talbot, Paola D Vermeer

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Anthony C RestainoCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, USA.
Maryam AhmadiDepartment of Biomedical and Molecular Sciences, Queen's University. Kingston. Canada.
Amin Reza NikpoorDepartment of Biomedical and Molecular Sciences, Queen's University. Kingston. Canada.
Austin WalzCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, USA.
Mohammad BaloodDepartment of Biomedical and Molecular Sciences, Queen's University. Kingston. Canada.
Tuany EichwaldDepartment of Biomedical and Molecular Sciences, Queen's University. Kingston. Canada.
Sebastien TalbotDepartment of Biomedical and Molecular Sciences, Queen's University. Kingston. Canada.
Paola D VermeerCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, USA.ORCID 0000-0003-2370-8223

Funding

The Impact of PD-1 Inhibition on Immune-Response to ChemoradiotherapyP20GM103548 · NIGMS · SANFORD RESEARCH/USD · PI MISKIMINS, W KEITH · 2012 to 2020
$20.8M
Pilot Project ProgramP30GM145398 · NIGMS · SANFORD RESEARCH/USD · PI W KEITH MISKIMINS · 2023 to 2026
$6.2M
Intra-tumoral neurons contribute to head and neck cancer painR01DE032712 · NIDCR · SANFORD RESEARCH/USD · PI Paola Drapkin Vermeer · 2023 to 2026
$1.8M
NIDCR NIH HHS R01 DE032712NIGMS NIH HHS P20 GM103548NIGMS NIH HHS P30 GM145398
6 · The paper itself

Abstract

Nociceptor neurons impact tumor immunity. Removing nociceptor neurons reduced myeloid-derived suppressor cell (MDSCs) tumor infiltration in mouse models of head and neck carcinoma and melanoma. Carcinoma-released small extracellular vesicles (sEVs) attract nociceptive nerves to tumors. sEV-deficient tumors fail to develop in mice lacking nociceptor neurons. Exposure of dorsal root ganglia (DRG) neurons to cancer sEVs elevated expression of Substance P, IL-6 and injury-related neuronal markers while treatment with cancer sEVs and cytotoxic CD8 T-cells induced an immunosuppressive state (increased exhaustion ligands and cytokines). Cancer patient sEVs enhanced DRG responses to capsaicin, indicating increased nociceptor sensitivity. Conditioned media from DRG and cancer cell co-cultures promoted expression of MDSC markers in primary bone marrow cells while DRG conditioned media together with cancer sEVs induced checkpoint expression on T-cells. Our findings indicate that nociceptor neurons facilitate CD8+ T cell exhaustion and enhance MDSC infiltration. Targeting nociceptor-released IL-6 emerges as a novel strategy to disrupt harmful neuro-immune interactions in cancer and enhance anti-tumor immunity.

Identifiers

PMID39253487
PMCPMC11382997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.